kth.sePublications KTH
Change search
Link to record
Permanent link

Direct link
Publications (10 of 65) Show all publications
Sadler, C. J., Creamer, A., Giang, K. A., Darmawan, K. K., Shamsabadi, A., Richards, D. A., . . . Stevens, M. M. (2025). Adding a Twist to Lateral Flow Immunoassays: A Direct Replacement of Antibodies with Helical Affibodies, from Selection to Application. Journal of the American Chemical Society, 147(14), 11925-11940
Open this publication in new window or tab >>Adding a Twist to Lateral Flow Immunoassays: A Direct Replacement of Antibodies with Helical Affibodies, from Selection to Application
Show others...
2025 (English)In: Journal of the American Chemical Society, ISSN 0002-7863, E-ISSN 1520-5126, Vol. 147, no 14, p. 11925-11940Article in journal (Refereed) Published
Abstract [en]

Immunoreagents, most commonly antibodies, are integral components of lateral flow immunoassays. However, the use of antibodies comes with limitations, particularly relating to their reproducible production, and poor thermal and chemical stability. Here, we employ phage display to develop affibodies, a class of nonimmunoglobulin affinity proteins based on a small three-helix bundle scaffold, against SARS-CoV-2 Spike protein. Subsequently, we demonstrate the utility and viability of affibodies to directly replace antibodies in lateral flow immunoassays. In addition, we highlight several physiochemical advantages of affibodies, including their ability to withstand exposure to high temperature and humidity while maintaining superior performance compared to their antibody counterparts. Furthermore, we investigate the adsorption mechanism of affibodies to the surface of gold nanoparticle probes via a His6-tag, introduced to also facilitate recombinant purification. Through molecular dynamics simulations, we elucidate the structural and physical characteristics of affibody dimers which result in high-performing detection probes when immobilized on nanoparticle surfaces. This work demonstrates that affibodies can be used as direct replacements to antibodies in immunoassays and should be further considered as alternatives owing to their improved physiochemical properties and modular design.

Place, publisher, year, edition, pages
American Chemical Society (ACS), 2025
National Category
Medical Biotechnology (Focus on Cell Biology, (incl. Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
urn:nbn:se:kth:diva-363138 (URN)10.1021/jacs.4c17452 (DOI)001455617300001 ()40135773 (PubMedID)2-s2.0-105001166397 (Scopus ID)
Note

QC 20250506

Available from: 2025-05-06 Created: 2025-05-06 Last updated: 2026-03-24Bibliographically approved
Giang, K. A., Nilvebrant, J., Liu, H., Káradóttir, H., Diao, Y., Svensson Gelius, S. & Nygren, P.-Å. (2025). An Anti-BCMA Affibody Affinity Protein for Therapeutic and Diagnostic Use in Multiple Myeloma. International Journal of Molecular Sciences, 26(11), Article ID 5186.
Open this publication in new window or tab >>An Anti-BCMA Affibody Affinity Protein for Therapeutic and Diagnostic Use in Multiple Myeloma
Show others...
2025 (English)In: International Journal of Molecular Sciences, ISSN 1661-6596, E-ISSN 1422-0067, Vol. 26, no 11, article id 5186Article in journal (Refereed) Published
Abstract [en]

B Cell Maturation Antigen (BCMA) has gained considerable attention as a target in directed therapies for multiple myeloma (MM) treatment, via immunoglobulin-based bispecific T cell engagers or CAR T cell strategies. We describe the development of alternative, non-immunoglobulin BCMA-recognising affinity proteins, based on the small (58 aa) three-helix bundle affibody scaffold. A first selection campaign using a naïve affibody phage library resulted in the isolation of several BCMA-binding clones with different kinetic profiles. One clone showing the slowest dissociation kinetics was chosen as the template for the construction of two second-generation libraries. Characterization of output clones from selections using these libraries led to the identification of clone 1-E6, which demonstrated low nM affinity to BCMA and high thermal stability. Biosensor experiments showed that 1-E6 interfered with the binding of BCMA to both its natural ligand APRIL and to the clinically evaluated anti-BCMA monoclonal antibody belantamab, suggesting overlapping epitopes. A fluorescently labelled head-to-tail homodimer construct of 1-E6 showed specific binding to the BCMA<sup>+</sup> MM.1s cell line in both flow cytometry and fluorescence microscopy. Taken together, the results suggest that the small anti-BCMA affibody 1-E6 could be an interesting alternative to antibody-based affinity units in the development of BCMA-targeted therapies and diagnostics.

Place, publisher, year, edition, pages
MDPI AG, 2025
Keywords
affibody, BCMA, multiple myeloma
National Category
Molecular Biology
Identifiers
urn:nbn:se:kth:diva-366566 (URN)10.3390/ijms26115186 (DOI)001505974100001 ()40507995 (PubMedID)2-s2.0-105007881196 (Scopus ID)
Note

QC 20250710

Available from: 2025-07-10 Created: 2025-07-10 Last updated: 2026-03-16Bibliographically approved
Nilvebrant, J., Moro, C. F., Papalanis, E., Novin, M. O., Ding, H., Li, R., . . . Nygren, P.-Å. (2025). An anti-CEA affibody showing high-definition staining in human pancreatic cancer tissue sections and selective tumor targeting in vivo. Translational Oncology, 61, Article ID 102512.
Open this publication in new window or tab >>An anti-CEA affibody showing high-definition staining in human pancreatic cancer tissue sections and selective tumor targeting in vivo
Show others...
2025 (English)In: Translational Oncology, ISSN 1944-7124, E-ISSN 1936-5233, Vol. 61, article id 102512Article in journal (Refereed) Published
Abstract [en]

We report development and characterization of small non-immunoglobulin affibody affinity proteins directed to the highly glycosylated human carcinoembryonic antigen-related adhesion molecule 5 (CEACAM5, CEA), and their use in immunohistochemical (IHC) analyses of human pancreatic cancer samples and for in vivo tumor imaging. A total of nineteen unique anti-CEA affibodies were identified from large phage display libraries constructed using combinatorial protein engineering of a small 58 amino acid three-helix bundle protein domain. Molecular modeling suggested that all enriched clones share a binding surface with several clustered tryptophan residues interacting with a hydrophobic patch in the N1 domain of CEA centered around a phenylalanine residue. One variant, designated as C9, exhibited the highest affinity in biosensor analyses and was reformatted into a 15 kDa homodimer expressed in Escherichia coli. The biotinylated form, C9-C9-Bio, was evaluated for its IHC performance on matched frozen and formalin-fixed, paraffin-embedded (FFPE) sections of human pancreatic cancer samples (n = 7). Compared to clinical-grade monoclonal antibodies II-7 and CEA31, as well as a polyclonal reagent, C9-C9-Bio demonstrated highly sensitive CEA detection with minimal background staining. Statistical analyses including intraclass correlation and Bland-Altman assessments revealed excellent agreement between C9-C9-Bio and the two monoclonal antibodies in FFPE tissue samples. Further, a <sup>99m</sup>Tc[Tc]-labeled C9-C9 construct showed CEA-dependent binding to human cancer cell lines in vitro, and selectively bound to CEA-expressing BxPC3 xenografts in mice when investigated as a tracer for in vivo imaging, allowing for a visualization of tumors after four hours. In summary, these findings highlight the potential use of the easily produced CEA-binding C9 affibody for various clinical applications, including IHC and medical imaging, and as a targeting moiety for directing various therapeutic modalities to CEA-expressing tumors.

Place, publisher, year, edition, pages
Elsevier BV, 2025
Keywords
Adenocarcinoma, Affibody, Affinity, Carcinoembryonic antigen, CEA, CEA31, CEACAM5, Clinical diagnostics, HRP, IHC, II-7, Immunohistochemistry, In vivo imaging, Pancreatic cancer, Phage display, Xenograft
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:kth:diva-369724 (URN)10.1016/j.tranon.2025.102512 (DOI)001562900500001 ()40882560 (PubMedID)2-s2.0-105014168909 (Scopus ID)
Note

QC 20250915

Available from: 2025-09-15 Created: 2025-09-15 Last updated: 2026-03-23Bibliographically approved
Nilvebrant, J., Thalén, N. B., Rockberg, J. & Malm, M. (2025). An Overview of Epitopes and Methods for Antibody Epitope Mapping. In: Methods in Molecular Biology: (pp. 1-11). Springer Nature, 2937
Open this publication in new window or tab >>An Overview of Epitopes and Methods for Antibody Epitope Mapping
2025 (English)In: Methods in Molecular Biology, Springer Nature , 2025, Vol. 2937, p. 1-11Chapter in book (Refereed)
Abstract [en]

Antibodies are protein molecules indispensable for many therapeutic, diagnostic, and research purposes due to their exquisite ability to selectively recognize and bind a given antigen. The particular area of the antigen recognized by the antibody is called the epitope, and mapping of such epitopes can provide important mechanistic insights and indicate for what applications an antibody might be useful. Even though the nature of epitopes can be complex, epitopes in protein antigens are broadly grouped into linear or discontinuous epitopes depending on the positioning of the epitope residues in the antigen sequence and the requirement of structure. Specialized methods for mapping the two different classes of epitopes have been developed. While different in their detail, all of the experimental methods rely on assessing the binding of the antibody to the antigen or a set of antigen mimics. Classical epitope mapping methods, utilizing truncated proteins, small numbers of synthesized peptides, and structural analyses of antibody-antigen complexes, have been significantly refined. Current state-of-the-art methods involve combinations of mutational scanning, protein display, and high throughput screening in conjunction with bioinformatic analyses of large datasets. In line with the significant development of in silico protein structure prediction in recent years, computerized approaches for epitope prediction have also matured considerably.

Place, publisher, year, edition, pages
Springer Nature, 2025
Keywords
Antibody, Antigen, Epitope, Epitope mapping, Peptide, Prediction, Structural biology
National Category
Medical Biotechnology (Focus on Cell Biology, (incl. Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
urn:nbn:se:kth:diva-377724 (URN)10.1007/978-1-0716-4591-8_1 (DOI)001654594200002 ()40593411 (PubMedID)2-s2.0-105010289133 (Scopus ID)
Note

QC 20260311

Available from: 2026-03-11 Created: 2026-03-11 Last updated: 2026-03-11Bibliographically approved
Nilvebrant, J. (2025). Binding Kinetics and Epitope Binning Using Surface Plasmon Resonance. In: Methods in Molecular Biology: (pp. 277-295). Springer Nature, 2937
Open this publication in new window or tab >>Binding Kinetics and Epitope Binning Using Surface Plasmon Resonance
2025 (English)In: Methods in Molecular Biology, Springer Nature , 2025, Vol. 2937, p. 277-295Chapter in book (Refereed)
Abstract [en]

The ability to quantify binding affinity of molecular interactions is an essential component of drug development and life science research. This chapter outlines the practical use of surface plasmon resonance spectroscopy to monitor protein-protein interactions with an emphasis on basic experimental design. A short overview of common epitope binning assays is also included.

Place, publisher, year, edition, pages
Springer Nature, 2025
Keywords
Affinity, Analyte, Binding kinetics, Biosensor, Epitope binning, Ligand, Surface plasmon resonance
National Category
Medical Biotechnology (Focus on Cell Biology, (incl. Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
urn:nbn:se:kth:diva-377739 (URN)10.1007/978-1-0716-4591-8_17 (DOI)001654594200018 ()40593427 (PubMedID)2-s2.0-105010288548 (Scopus ID)
Note

Part of ISBN 978-1-0716-4590-1; 978-1-0716-4593-2; 978-1-0716-4591-8

QC 20260311

Available from: 2026-03-11 Created: 2026-03-11 Last updated: 2026-03-11Bibliographically approved
Ek, M., Nilvebrant, J., Nygren, P.-Å., Ståhl, S., Lindberg, H. & Löfblom, J. (2025). Design and development of a sortilin-targeting miniprotein for the treatment of FTD. Paper presented at Alzheimer's Association International Conference 2025, Toronto, July 27-31. Alzheimer's & Dementia: Journal of the Alzheimer's Association, 21(S5), 100961
Open this publication in new window or tab >>Design and development of a sortilin-targeting miniprotein for the treatment of FTD
Show others...
2025 (English)In: Alzheimer's & Dementia: Journal of the Alzheimer's Association, ISSN 1552-5260, E-ISSN 1552-5279, Vol. 21, no S5, p. 100961-Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Heterozygous loss-of-function mutations in the gene encoding progranulin (GRN) are causative in around 5-10% of frontotemporal dementia (FTD) cases. These mutations lead to a more than 50% reduction of progranulin levels in the plasma and cerebrospinal fluid of mutation carriers compared to healthy controls. Increasing the progranulin levels in FTD-GRN patients via inhibition of sortilin-mediated progranulin degradation has shown promise as a therapeutic strategy, as exemplified by Alector's latozinemab, currently in phase 3 clinical trials. Here we detail the development of an anti-sortilin affibody-based miniprotein as a non-immunoglobulin alternative, offering potential advantages due to its small size and cost-effective production.

METHOD: Sortilin-binding affibodies were selected by phage display and subsequently genetically fused to short peptides derived from the progranulin C-terminus. The resulting miniproteins were characterized in terms of affinity, structure, stability, and their ability to increase extracellular progranulin levels in a clearance assay using progranulin-secreting, sortilin-expressing U-251 MG cells.

RESULT: A set of moderate-affinity sortilin-binding affibodies were obtained from phage display selections. Following genetic fusion with short peptides derived from the progranulin C-terminus and optimization of the fusion constructs, a lead candidate with 185 pM affinity for sortilin was obtained. The affibody-peptide fusion, but not its parental affibody or peptide, was capable of elevating extracellular progranulin levels in vitro with similar potency as latozinemab.

CONCLUSION: A sortilin-binding affibody-based miniprotein was developed and optimized, performing on par with latozinemab in in vitro functional studies. Affibody-based miniproteins provide a promising alternative to immunoglobulins in cases such as the present, where Fc functions are undesirable, and long-term high-dose antibody treatments risk becoming prohibitively expensive.

Place, publisher, year, edition, pages
Wiley, 2025
National Category
Neurology
Identifiers
urn:nbn:se:kth:diva-374951 (URN)10.1002/alz70859_100961 (DOI)41448167 (PubMedID)
Conference
Alzheimer's Association International Conference 2025, Toronto, July 27-31
Note

QC 20260626

Available from: 2026-01-12 Created: 2026-01-12 Last updated: 2026-06-26Bibliographically approved
Rockberg, J., Nilvebrant, J., Malm, M. & Thalén, N. (Eds.). (2025). Epitope Mapping Protocols. Springer Nature
Open this publication in new window or tab >>Epitope Mapping Protocols
2025 (English)Collection (editor) (Refereed)
Abstract [en]

This detailed new edition explores methodologies for the characterization of antibody-antigen interactions tailored to different applications and requirements. Beginning with an overview of key concepts and definitions related to antibody epitopes, the book continues with sections on structural biology methods, display technologies to analyze libraries of proteins or protein arrays, techniques based on protein labeling, as well as computational approaches and binding assays that rely on binding interactions or competition. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step and readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.

Place, publisher, year, edition, pages
Springer Nature, 2025. p. xi, 394
Series
Methods in Molecular Biology, ISSN 1064-3745 ; 2937
National Category
Immunology in the Medical Area
Identifiers
urn:nbn:se:kth:diva-378191 (URN)10.1007/978-1-0716-4591-8 (DOI)001654594200024 ()978-1-0716-4593-2 (ISBN)978-1-0716-4591-8 (ISBN)978-1-0716-4590-1 (ISBN)
Note

QC 20260318

Available from: 2026-03-18 Created: 2026-03-18 Last updated: 2026-06-30Bibliographically approved
Tolmachev, V., Papalanis, E., Nilvebrant, J., Oroujeni, M., Li, R., Bezverkhniaia, E., . . . Nygren, P.-Å. (2025). Feasibility of imaging CEACAM5 expressing xenografts using radiolabeled affibody molecules. Nuclear Medicine and Biology, 150-151, 109293
Open this publication in new window or tab >>Feasibility of imaging CEACAM5 expressing xenografts using radiolabeled affibody molecules
Show others...
2025 (English)In: Nuclear Medicine and Biology, ISSN 0969-8051, E-ISSN 1872-9614, Vol. 150-151, p. 109293-Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Elsevier BV, 2025
National Category
Radiology and Medical Imaging
Identifiers
urn:nbn:se:kth:diva-376652 (URN)10.1016/j.nucmedbio.2025.109293 (DOI)001632358100055 ()
Note

QC 20260223

Available from: 2026-02-23 Created: 2026-02-23 Last updated: 2026-03-24Bibliographically approved
Rockberg, J., Nilvebrant, J., Malm, M. & Thalén, N. (2025). Preface. In: Methods in Molecular Biology: (pp. v-vi). Humana Press Inc., 2937
Open this publication in new window or tab >>Preface
2025 (English)In: Methods in Molecular Biology, Humana Press Inc. , 2025, Vol. 2937, p. v-viChapter in book (Other academic)
Place, publisher, year, edition, pages
Humana Press Inc., 2025
National Category
Molecular Biology
Identifiers
urn:nbn:se:kth:diva-383756 (URN)2-s2.0-105014439651 (Scopus ID)
Note

QC 20260629

Available from: 2026-06-29 Created: 2026-06-29 Last updated: 2026-06-29Bibliographically approved
Ek, M., Nilvebrant, J., Nygren, P.-Å., Ståhl, S., Lindberg, H. & Löfblom, J. (2024). An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation. Frontiers in Immunology, 15, Article ID 1437886.
Open this publication in new window or tab >>An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation
Show others...
2024 (English)In: Frontiers in Immunology, E-ISSN 1664-3224, Vol. 15, article id 1437886Article in journal (Refereed) Published
Abstract [en]

Heterozygous loss-of-function mutations in the GRN gene are a common cause of frontotemporal dementia. Such mutations lead to decreased plasma and cerebrospinal fluid levels of progranulin (PGRN), a neurotrophic factor with lysosomal functions. Sortilin is a negative regulator of extracellular PGRN levels and has shown promise as a therapeutic target for frontotemporal dementia, enabling increased extracellular PGRN levels through inhibition of sortilin-mediated PGRN degradation. Here we report the development of a high-affinity sortilin-binding affibody-peptide fusion construct capable of increasing extracellular PGRN levels in vitro. By genetic fusion of a sortilin-binding affibody generated through phage display and a peptide derived from the progranulin C-terminus, an affinity protein (A3-PGRNC15*) with 185-pM affinity for sortilin was obtained. Treating PGRN-secreting and sortilin-expressing human glioblastoma U-251 cells with the fusion protein increased extracellular PGRN levels up to 2.5-fold, with an EC50 value of 1.3 nM. Our results introduce A3-PGRNC15* as a promising new agent with therapeutic potential for the treatment of frontotemporal dementia. Furthermore, the work highlights means to increase binding affinity through synergistic contribution from two orthogonal polypeptide units.

Place, publisher, year, edition, pages
Frontiers Media SA, 2024
Keywords
protein engineering, affibody molecule, sortilin (SORT1), progranulin (GRN), frontotemporal dementia (FTD), latozinemab, phage display
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
urn:nbn:se:kth:diva-352993 (URN)10.3389/fimmu.2024.1437886 (DOI)001294994300001 ()39185427 (PubMedID)2-s2.0-85201640842 (Scopus ID)
Note

QC 20240912

Available from: 2024-09-12 Created: 2024-09-12 Last updated: 2026-02-10Bibliographically approved
Organisations
Identifiers
ORCID iD: ORCID iD iconorcid.org/0000-0002-6104-6446

Search in DiVA

Show all publications